KKR has acquired a majority stake in HealthCare Royalty Partners, pushing the investment firm further into the healthcare ...

KKR & Co. Inc., a leading global investment firm, today announced that it has acquired a majority ownership stake in HealthCare Royalty Partners (HCRx), a leading biopharma royalty acquisition company ...

Investment firm KKR (NYSE:KKR) announced on Wednesday the acquisition of a majority stake in biopharma royalty acquisition company, HealthCare Royalty Partners. The acquisition marks KKR's expansion ...

KKR executives said strong momentum in their business gave them confidence on Thursday of beating earnings targets for 2026, ...

As part of the transaction, HCRx Chairman and CEO Clarke Futch will continue to lead the HCRx team and will maintain an ongoing substantial minority interest in HCRx.

Under the terms of the agreement, Ardelyx will receive from HealthCare Royalty a $10 million upfront payment, an additional $5 million following Kyowa Kirin's receipt of regulatory approval to ...

MacroGenics (MGNX) received $70 million upfront cash payment from Sagard Healthcare Partners (Sagard) MacroGenics’ cash runway extended through first half of 2027 ROCKVILLE, MD, June 10, 2025 ...

HealthCare Royalty Partners (“HCR") is a private investment firm that purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage biopharmaceutical assets.

About HealthCare Royalty Partners HCR is a private investment firm that purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage life science assets.

HealthCare Royalty Partners (“HCR”) is a private investment firm that purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage life science assets.

Under the terms of the royalty purchase agreement, MacroGenics received a $70 million upfront payment for the sale of its royalty rights on global net sales of ZYNYZ. Following Sagard’s receipt ...